NRIX
Price
$25.67
Change
+$0.26 (+1.02%)
Updated
Sep 22 closing price
Capitalization
2.64B
16 days until earnings call
Intraday BUY SELL Signals
OCUL
Price
$10.50
Change
+$0.51 (+5.11%)
Updated
Sep 22 closing price
Capitalization
2.19B
47 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

NRIX vs OCUL

NRIX vs OCUL Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
NRIX vs. OCUL commentary
Sep 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NRIX is a Hold and OCUL is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
NRIX vs OCUL: Fundamental Ratings
NRIX
OCUL
OUTLOOK RATING
1..100
5973
VALUATION
overvalued / fair valued / undervalued
1..100
47
Fair valued
39
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
3558
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OCUL's Valuation (39) in the Pharmaceuticals Other industry is in the same range as NRIX (47) in the null industry. This means that OCUL’s stock grew similarly to NRIX’s over the last 12 months.

OCUL's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as NRIX (100) in the null industry. This means that OCUL’s stock grew similarly to NRIX’s over the last 12 months.

OCUL's SMR Rating (98) in the Pharmaceuticals Other industry is in the same range as NRIX (98) in the null industry. This means that OCUL’s stock grew similarly to NRIX’s over the last 12 months.

NRIX's Price Growth Rating (35) in the null industry is in the same range as OCUL (58) in the Pharmaceuticals Other industry. This means that NRIX’s stock grew similarly to OCUL’s over the last 12 months.

NRIX's P/E Growth Rating (100) in the null industry is in the same range as OCUL (100) in the Pharmaceuticals Other industry. This means that NRIX’s stock grew similarly to OCUL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NRIXOCUL
RSI
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
76%
MACD
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 6 days ago
82%
Bullish Trend 14 days ago
80%
Declines
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 7 days ago
83%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
86%
Aroon
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
90%
COMPARISON
Comparison
Sep 23, 2026
Stock price -- (NRIX: $25.41 vs. OCUL: $9.99)
Brand notoriety: NRIX and OCUL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NRIX: 129% vs. OCUL: 83%
Market capitalization -- NRIX: $2.64B vs. OCUL: $2.19B
NRIX [@Biotechnology] is valued at $2.64B. OCUL’s [@Biotechnology] market capitalization is $2.19B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $128.84B. The average market capitalization across the [@Biotechnology] industry is $2.2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NRIX’s FA Score shows that 0 FA rating(s) are green while OCUL’s FA Score has 0 green FA rating(s).

  • NRIX’s FA Score: 0 green, 5 red.
  • OCUL’s FA Score: 0 green, 5 red.
According to our system of comparison, NRIX is a better buy in the long-term than OCUL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NRIX’s TA Score shows that 4 TA indicator(s) are bullish while OCUL’s TA Score has 5 bullish TA indicator(s).

  • NRIX’s TA Score: 4 bullish, 5 bearish.
  • OCUL’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, OCUL is a better buy in the short-term than NRIX.

Price Growth

NRIX (@Biotechnology) experienced а -0.43% price change this week, while OCUL (@Biotechnology) price change was -6.81% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +27.63%. For the same industry, the average monthly price growth was -6.27%, and the average quarterly price growth was +7.77%.

Reported Earning Dates

NRIX is expected to report earnings on Oct 09, 2026.

OCUL is expected to report earnings on Nov 09, 2026.

Industries' Descriptions

@Biotechnology (+27.63% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
NRIX
Daily Signal:
Gain/Loss:
OCUL
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
DRNZ20.940.32
+1.55%
REX Drone ETF (DRNZ)
VFMO229.632.32
+1.02%
Vanguard U.S. Momentum Factor ETF (VFMO)
DDTN21.050.18
+0.88%
Innovator Equity Dual Directional 10 Buffer ETF - November (DDTN)
GLDN16.63-0.22
-1.33%
Nicholas Gold Income ETF (GLDN)
BOIL19.47-0.55
-2.75%
ProShares Ultra Bloomberg Natural Gas (BOIL)

NRIX and

Correlation & Price change

A.I.dvisor indicates that over the last year, NRIX has been loosely correlated with KYMR. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if NRIX jumps, then KYMR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NRIX
1D Price
Change %
NRIX100%
-0.12%
KYMR - NRIX
58%
Loosely correlated
-0.07%
KURA - NRIX
45%
Loosely correlated
-1.11%
BCYC - NRIX
45%
Loosely correlated
-0.55%
GPCR - NRIX
45%
Loosely correlated
+5.17%
RCUS - NRIX
45%
Loosely correlated
+2.81%
More